Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation
View Patent ↗Cell-based compositions and methods of their use to inhibit an adverse immune response such as graft versus host disease or rejection of transplanted tissue in a transplant recipient that is histocompatibility mismatched to the transplant donor are disclosed. The compositions and methods utilize postpartum-derived cells, such as cells derived from the placenta or umbilicus.
1. A method for inhibiting an adverse immune response in a transplant recipient in need thereof comprising:
(i) identifying a transplant recipient that is histocompatibility-mismatched to a transplant donor,
(ii) Identifying a composition of human umbilical cord tissue cells exhibiting a lower stimulation index of naïve CD4+ T-cells, wherein the identification is by mixed lymphocyte reaction (MLR), wherein the MLR comprises (a) a population of lymphocytes allogenic to the transplant recipient and (b) a composition of human umbilical cord tissue cells allogenic to the transplant recipient, wherein the composition of human umbilical cord tissue cells is a homogeneous population of allogeneic umbilicus-derived cells derived from human umbilical cord tissue free of blood, said cells being capable of self-renewal and expansion in culture, wherein the cells are capable of growth in an atmosphere containing oxygen from about 5% to at least about 20%, and wherein said homogeneous population comprise having the following characteristics:
(a) potential for at least 40 doublings in culture;
(b) production of CD 10, CD 13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(c) lack of production of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD 178, B7-H2, HLA-G, and HLA-DR,DP,DQ, as detected by flow cytometry;
(d) expression of interleukin 8; reticulon 1; and chemokine (C-X-C motif) ligand 3;
(e) secretion of MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, I309, MDC, and TIMP1; and
(f) lack of secretion of TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF, as detected by ELISA,
(iii) administering the identified composition of homogenous human umbilical cord tissue cell to the transplant recipient in an amount effective for inhibiting the adverse immune response in the transplant recipient that is histocompatibility-mismatched to the transplant donor,
wherein the identified composition inhibits the adverse immune response in the transplant recipient that is histocompatibility-mismatched to the transplant donor.
2. The method of claim 1 , wherein the adverse immune response is graft versus host disease.
3. The method of claim 1 , wherein the adverse immune response is rejection of the transplanted tissue.
4. The method of claim 1 wherein the cell composition is administered by injection or infusion.
5. The method of claim 1 , wherein the cell composition is administered by implantation of a device, scaffold or matrix implanted in the transplant recipient.
6. The method of claim 1 , wherein the cell composition is administered with at least one other allogeneic cell type.
7. The method of claim 6 , wherein the at least one other allogeneic cell type is administered simultaneously with, or before, or after, the umbilicus-derived cells.
8. The method of claim 1 , wherein the cell composition is administered with at least one other agent for treating the adverse immune response.
9. The method of claim 8 , wherein the at least one other agent is administered simultaneously with, or before, or after, the umbilicus-derived cells.
10. The method of claim 8 , wherein the at least one other agent is one or more of an antithrombogenic agent, an anti-inflammatory agent, an immunosuppressive agent, an immunomodulatory agent, or an antiapoptotic agent.
11. A pharmaceutical composition for inhibiting an adverse immune response in a transplant recipient that is histocompatibility-mismatched to the transplant donor, comprising a pharmaceutically acceptable carrier and a composition of human umbilical cord tissue cells free of blood, said cells being capable of self-renewal and expansion in culture, wherein the cells are capable of growth in an atmosphere containing oxygen from about 5% to at least about 20%, and wherein said homogeneous population comprise having the following characteristics:
(a) potential for at least 40 doublings in culture;
(b) production of CD 10, CD 13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(c) lack of production of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD 178, B7-H2, HLA-G, and HLA-DR,DP,DQ, as detected by flow cytometry;
(d) expression of interleukin 8; reticulon 1; and chemokine (C—X—C motif) ligand 3;
(e) secretion of MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, I309, MDC, and TIMP1; and
(f) lack of secretion of TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF, as detected by ELISA.
12. The pharmaceutical composition of claim 11 , wherein the adverse immune response is graft versus host disease.
13. The pharmaceutical composition of claim 11 , wherein the adverse immune response is rejection of the transplanted tissue.
14. The pharmaceutical composition of claim 11 , formulated for administration by injection or infusion.
15. The pharmaceutical composition of claim 11 , formulated for administration by implantation of a device, scaffold or matrix implanted in the transplant recipient.
16. The pharmaceutical composition of claim 11 , comprising at least about 50% human umbilical cord tissue cells.
17. The pharmaceutical composition of claim 11 , comprising a substantially homogeneous population of human umbilical cord tissue cells.
18. The pharmaceutical composition of claim 11 , comprising at least one other cell type.
19. The pharmaceutical composition of claim 11 , comprising at least one other agent for treating the adverse immune response.
20. The pharmaceutical composition of claim 19 , wherein the at least one other agent is one or more of an antithrombogenic agent, an anti-inflammatory agent, an immunosuppressive agent, an immunomodulatory agent, or an antiapoptotic agent.
21. A method for inhibiting an adverse immune response in a transplant recipient in need thereof comprising
administering an effective amount of a cell composition to a transplant recipient that is histocompatibility-mismatched to a transplant donor,
wherein the cell composition inhibits the adverse immune response in the transplant recipient that is histocompatibility-mismatched to the transplant donor,
wherein the cell composition comprises a pharmaceutically acceptable carrier and a homogeneous population of allogeneic umbilicus-derived cells derived from human umbilical cord tissue free of blood, said cells being capable of self-renewal and expansion in culture,
wherein the cells and are capable of growth in an atmosphere containing oxygen from about 5% to at least about 20%, and wherein the cells comprise the following characteristics:
(a) potential for at least 40 doublings in culture;
(b) production of CD 10, CD 13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(c) lack of production of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD 178, B7-H2, HLA-G, and HLA-DR,DP,DQ, as detected by flow cytometry;
(d) expression of interleukin 8; reticulon 1; and chemokine (C—X—C motif) ligand 3;
(e) secretion of MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, I309, MDC, and TIMP1; and
(f) lack of secretion ofTGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF, as detected by ELISA.
22. The method of claim 21 , wherein the adverse immune response is graft versus host disease.
23. The method of claim 21 , wherein the adverse immune response is rejection of the transplanted tissue.
24. The method of claim 21 , wherein the cell composition is administered by injection or infusion.
25. The method of claim 21 , wherein the cell composition is administered by implantation of a device, scaffold or matrix implanted in the transplant recipient.
26. The method of claim 1 , wherein the method comprises co-administration of the cell composition and an immunosuppressive agent.
27. The method of claim 21 , wherein the method comprises co-administration of the cell composition and an immunosuppressive agent.